NATCO Pharma Plans Rights Issue to Raise Capital
NATCO Pharma proposes a new rights issue to raise additional capital. The company has released a draft offer letter detailing the proposed terms. Source: Livesquawk
Stock news timeline · NATCOPHARM
Natco Pharma
News timeline · Last 30 days
23 Aug 2026 – 21 Sep 2026 · Times in IST
- Timeline updates
- 18
- Bullish
- 5
- Neutral
- 13
- Bearish
- 0
- Active days
- 7
News timeline
Showing 18 of 18 updates · Newest first
No matching updates
Change the keyword or sentiment above, then click Apply.
Wednesday, 09 Sep 20264 updates
NATCO Pharma: Suggests New Rights Issue With Draft Offer Letter Attached
Natco Pharma: Board Approves Raising Funds Up To ₹1,300 Crore
Natco Pharma OKs ₹1,300 Cr Rights Issue; Revises Demerger Plan
Natco Pharma's board approves ₹1,300 crore rights issue with ₹2 face value equity shares. Board forms Fund-Raising Committee and plans to revise demerger scheme post rights issue. Source: BSE
Friday, 04 Sep 20262 updates
Natco Pharma Eyes Fundraising via Equity for Future Needs
Natco Pharma plans to discuss raising funds via equity shares or securities. The move aims to support future financing needs per board discussions. Source: Livesquawk
Natco Pharma: Board Plans To Discuss Raising Funds Through Equity Shares Or Other Securities.
Wednesday, 02 Sep 20262 updates
Natco Pharma: To Hold Analyst And Investor Meeting On September 7 At 10 AM
Natco Pharma to Host Investor Meet on 7th Sept 2026 in Hyderabad
Natco Pharma announces investor meet on 7th Sept 2026 in Hyderabad. The meeting, organised by Antique Stock Broking, will share no UPSI. Source: BSE
Wednesday, 26 Aug 20261 update
Natco Pharma Promoter Sells 50K Shares in Off-Market Deal
Natco Pharma promoter Durga Devi Nannapaneni sold 50,000 shares, 0.03% of share capital. Transaction mode was off-market. Source: ScoutQuest
Tuesday, 25 Aug 20263 updates
Natco Pharma Ups eGenesis Stake to $22M
Natco Pharma invests $14M in eGenesis via subsidiaries, raising total to $22M. Investment in convertible promissory notes with 8% interest; eGenesis works on organ genome engineering. Source: ScoutQuest
NATCO Pharma Ups Egenesis Stake to $22M for Organ Engineering
NATCO Pharma invests $14M in Egenesis via subsidiaries, raising total investment to $22M. Egenesis specializes in genome-engineering to create transplantable organs. Source: Livesquawk
NATCO Pharma: Co. Invests $14 Million In Egenesis, Inc. Via Subsidiaries, Raising Total Investment To $22 Million; Egenesis Works On Creating Transplantable Organs With Genome Engineering.
Monday, 24 Aug 20264 updates
Natco Pharma to Host Investor Meet on Aug 27 for Business Updates
Natco Pharma scheduled to meet analysts and investors on Aug 27. The meeting may include updates on business performance and outlook. Source: Livesquawk
Natco Pharma: To Meet With Analysts And Investors On August 27
Natco Pharma to Join Investor Meets in Mumbai, Hong Kong
Natco Pharma officials to join investor meets in Mumbai and Hong Kong. No UPSI will be shared; presentation available on Natco's official website. Source: BSE
USFDA Observations Hit Caplin, Natco; Jubilant Gains on New Approval
USFDA issued 10 observations to Caplin Point, 4 to Natco Pharma, and 1 to Aurobindo Pharma post inspections. Jubilant Pharmova's US arm received approval for a new product line. Shares of all 4 pharma firms saw varied movements. Source: CNBC TV 18
Sunday, 23 Aug 20262 updates
Natco Pharma Boosts Adcock Stake to 49% with ₹1,060 Cr Investment
Natco Pharma increased its stake in Adcock Ingram to 49%, investing Rs. 1,060 cr to strengthen its South African presence. Natco plans product launches in South Africa by 2028, leveraging Adcock's distribution, R&D synergies, and semaglutide opportunities. Source: Trade Brains
RIL Ventures into Chemicals, Agri; AGM Clears Key Resolutions
RIL expands its portfolio into chemicals/agriculture, AGM approves major resolutions. FDA observations impact Caplin, NATCO, Choksi; Mobile & EMS stocks gain from govt scheme. Source: CNBC TV 18